Metabasis' Diabetes Drug Fails Trial

Metabasis Therapeutics Inc.'s (MBRX) diabetes drug CS-917 failed a mid-stage clinical trial sending shares of the biopharmaceutical plummeting $3.75 to close at $3.15.